Avodart may also prevent prostate cancer

Avodart may also prevent prostate cancer

According to a new study drug used to treat a benign prostate condition may also be effective to prevent prostate cancer.

Drug dutasteride under the brand name of Avodart reduced the risk of developing cancer in 3,305 men.

GlaxoSmithKline, manufacturer of Avodart, is now looking forward for approval of drug from Food and Drug Administration.

According to a new study conducted at 250 sites in 42 countries, dutasteride is more effective in reducing the risk of prostate tumors than a similar drug, finasteride.

Being already used to shrink enlarged prostate, this drug is already available in market. Doctors can prescribe it to patients without waiting for its approval from Food and Drug Administration (FDA).

Merck & Co. Inc. drugs dutasteride and finasteride, sold under brand name of Proscar, are already approved for treating benign prostatic hyperplasia or BPH.

The wholesale price of Avodart is $3.23 per pill which is costly as compare to Finasteride

The most common cancer among men after skin cancer is Prostate cancer. On an average the men affected by Prostate cancer every year are 192,000 and out of which 27,000 died every year.

Share Share